title: [Treatment of immune thrombocytopenia: a retrospective study of 40 patients].
abstract: OBJECTIVE
  Immune thrombocytopenia (ITP) is an auto-immune disease associating a peripheral platelet destruction without increased central production.
  
  
  METHODS
  Forty patients with chronic ITP were retrospectively analyzed for clinical and biological presentation and response to treatment.
  
  
  RESULTS
  Mean age at diagnosis was 54 years. ITP was revealed by hemorrhage in 65 % of the patients. Despite very low platelet count, no life threatening hemorrhage was observed. Platelet associated antibodies were found in 66 %, usually directed against GPIIb/IIIa. Corticosteroids were used as first line treatment, with response in 54 %, and relapse in 86 %. A response was observed in 42.1 % with dapsone, which was well tolerated, a relapse occurring in 37.5 % of the patients. Rituximab (RTX) allowed a response rate of 42.1 %, prolonged in 40 % of the patients. A response was achieved in 42.9 % cases after splenectomy, without any relapse. No factor was identified to predict the response to treatment.
  
  
  CONCLUSIONS
  ITP is a rare disorder occurring most frequently in middle aged patients. Because of high relapse or no response rates, many treatments should be used. Dapsone offers a good efficacy without major side effects. RTX is well tolerated and allows a good response rate. The use of new agents like thrombopoietin receptor agonist or new therapeutics against B lymphocytes should be defined.
authors.affiliation: Service de médecine interne et immunologie clinique, centre de compétence des cytopénies auto-immunes de Bourgogne Franche-Comté, hôpital du Bocage, CHU de Dijon, 2, boulevard Maréchal-de-Lattre-de-Tassigny, 21079 Dijon cedex, France. sylvain.audia@chu-dijon.fr
authors.forename: S
authors.initials: S
authors.lastname: Audia
authors.forename: D
authors.initials: D
authors.lastname: Lakomy
authors.forename: J
authors.initials: J
authors.lastname: Guy
authors.forename: V
authors.initials: V
authors.lastname: Leguy-Seguin
authors.forename: S
authors.initials: S
authors.lastname: Berthier
authors.forename: S
authors.initials: S
authors.lastname: Aho
authors.forename: B
authors.initials: B
authors.lastname: Lorcerie
authors.forename: B
authors.initials: B
authors.lastname: Bonnotte
mesh_terms: D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D000069283:Rituximab; D013156:Splenectomy; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007155:Immunologic Factors; D000069283:Rituximab; D003622:Dapsone